Available online on 15.9.2016 at <http://ujpr.org>
Universal Journal of Pharmaceutical Research
 An International Peer Reviewed Journal

Open access to Pharmaceutical research
 This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial Share Alike 4.0 License which permits unrestricted non commercial use, provided the original work is properly cited

Volume 1, Issue 1, 2016

Open Access

REVIEW ARTICLE

EBOLA VIRUS DISEASE AND ITS COMPLICATIONS

Raj K Keservani¹ , Anil K Sharma² , Urmila Jarouliya³ , Amit Kumar Singh⁴

¹School of Pharmaceutical Sciences, Rajiv Gandhi Proudyogiki Vishwavidyalaya, Bhopal, 462033, India.

²Department of Pharmaceutics, Delhi Institute of Pharmaceutical Sciences and Research, New Delhi, 110017, India.

³School of Studies in Biotechnology, Jiwaji University, Gwalior (M.P.), 474011, India.

⁴Faculty of Pharmaceutics, United Institute of Pharmacy, UCER, Allahabad, 211008, India.

ABSTRACT

In African countries Ebola virus has been responsible for several deaths. In addition to being a global health concern, the virus is also considered a potential biological threat. Ebola viruses are incompletely understood pathogens that cause severe, often fatal, illnesses in humans and non-human primates. Ebola virus disease affects most of the human being and finally mortality rate increases in that country. Most of the countries are on alert for the ebola virus because peoples have worked within the boundaries of the affected area of Africa. Such people are not permitted to enter in the resident country without proper test at airport or other places. In this review we have discussed ebola virus disease and it affects the peoples worldwide.

Keywords: Ebola virus, Ebola Virus Disease (EVD), filoviruses, hemorrhagic fever.

Article Info: Received 3 August 2016; Revised 10 September; Accepted 15 October, Available online 15 November 2016

Cite this article-

Keservani RK, Sharma AK, Jarouliya U, Singh AK. Ebola virus disease and its complications. Universal Journal of Pharmaceutical Research 2016; 1(1): 30-32.

DOI: <http://doi.org/10.22270/ujpr.v1i1.RW1>

Address for Correspondence:

Raj K Keservani, School of Pharmaceutical Sciences, Rajiv Gandhi Proudyogiki Vishwavidyalaya, Bhopal, 462033, India, Tel: +91-7007824306, E-mail: rajksops@gmail.com

INTRODUCTION

Ebola is a rare but deadly virus that causes bleeding inside and outside the body. As the virus spreads through the body, it damages the immune system and body organs. Ultimately, it causes levels of blood-clotting cells to drop, which eventually leads to severe uncontrollable bleeding. The disease, also known as Ebola hemorrhagic fever or Ebola virus, kills up to 90% of people having Ebola infection. Ebola cases shown up in Central and West Africa have proved grave enough to cause death of patients. Ebola can spread from country to country whenever people travel. Ebola could appear like the flu or other illnesses. Symptoms show up to 2-21 days following infection¹⁻⁴. There were different cases and deaths from EVD in Guinea, Liberia, Nigeria, and Sierra Leone on 31 July 2014. The spread of EVD between and within the three neighboring countries accounting for the majority of the cases noted so far Guinea, Liberia, and Sierra Leone is due to high cross-border movement and the introduction of EVD in additional neighboring countries in the sub region might not be excluded due to the existence of similarly porous borders⁵.

Structure of ebola virus

EBOV (Ebola Virus) carries a negative-sense RNA genome in virions that are cylindrical/tubular, and

contain viral envelope, matrix, and nucleocapsid components. The overall cylinders are generally approx. 80nm in diameter, and having a virally encoded glycoprotein (GP) projecting as 7-10 nm long spikes from its lipid bilayer surface⁶ (Figure 1).

The Ebola has characteristic "threadlike" structure, however, a more general morphologic characteristic of filoviruses (alongside their GP-decorated viral envelope, RNA nucleocapsid, etc⁷.

Figure 1: Structure of Ebola virus (Transmission electron micrograph).

Etiology

The species is avirological taxon species included the genus in Ebolavirus family Filoviridae (members known as Filovirus)⁸, order Mononegavirales⁹. The

Zaire ebolavirus species is also the type species (reference or example species) for ebolavirus. Its natural reservoir is bats, particularly fruit bats. The EBOV genome is approximately 19,000 base pairs long. It encodes 7 structural proteins: nucleoprotein (NP), polymerase cofactor (VP35), (VP40), GP, transcription activator (VP30), VP24, and RNA polymerase (L)¹⁰ (Figure 2). The virulent nature of the virus poses difficulties in its investigations.

Spread

Ebola spreads to people by contact with the skin or body fluids of an infected animal, like a monkey, chimp, or fruit bat. Subsequently it moves from one person to another person by the same way. Persons who care for a sick person or bury someone who has died from the disease often get it. Ebola also spreads by touching contaminated needles or surfaces. Ebola cannot spread through air, water and food, handling the meat from infected animals, coming into contact with the infected person's blood. A person who has Ebola but has no symptoms cannot spread the disease, either^{11,12}.

Figure 2: Virion structure of Ebola virus.

Pathogenesis

Ebola virus enters into the body through the mucous membrane, rupturing skin and via the parenteral route. Due to outbreak conditions all data of ebola virus pathogenesis obtained by laboratory experiments on guinea pigs, mice and other nonhuman primates¹³.

Attacking system of ebola virus in human

When Ebola enters into the human body system, ebola virus protein called VP24 binds with the human host protein known as KPNA5. KPNA5's mainly responsible for the communication between cells and transfer signal into and out of nucleus. It works just like a messenger. After that KPNA5 transfers all these signals to nucleus of other structures of the cells. These signals regulate various functions in an organism including immune response. When Ebola protein VP24 binds with the messenger protein STAT1, important immune signal transmission is blocked; STAT1 is the transporter inside the nucleus and activates the genes for antiviral responses as per Daisy Leung. Inhibition of PY-STAT1 by eVP-24 is due to direct competitions by eVP-24 for NPI-1 subfamily KPNA binding. Nucleus receives STAT-1 protein; it sounds like alarm and releases interferons to combat against virus,

bacteria or whoever other pathogen is attacking the cells. The immune system can't communicate properly because of VP24 is still stationed at STAT1 seat¹⁴ (Figure 3).

Figure 3: Schematic representation of Ebola virus killing host system.

Symptoms

Ebola symptoms include headache high fever, Joint aches, muscle aches, weakness, sore throat, pain in stomach and lack of appetite. Bleeding occurs within the body, as well as from the eyes, ears, and nose upon worsening of disease. Some people will vomit or cough up blood, have bloody diarrhoea, and get a rash¹⁵. Transaminitis, leukopenia, thrombocytopenia, coagulations abnormalities and renal abnormalities often occur in patient with ebola virus by laboratory findings¹⁶.

Diagnosis

Doctors may prescribe tests like CBC (Complete Blood Count), coagulation studies (a test to check for the amount of time a person's blood needs to clot), viral antigen testing (a test to check for the presence of the viral antigen) and a liver function test.

Prognosis

As per WHO reports, on an average, 80% of the people infected with Ebola virus do die. Their death is usually due to a drop in their blood pressure and failure of organs³.

PREVENTION

Control

The basic hygiene is of importance and a must be followed in order to prevent the onset of the condition. Simple activities like washing your hands well, drinking water from a clean source, maintaining general hygiene and cooking your meat well, can all serve as precautionary measures⁴.

Treatment

Standard treatment currently consists of supportive therapy, including maintenance of blood volume and electrolyte balance, as well as analgesics and standard nursing care¹⁷. Progression of Ebola virus in infected mice is inhibited by some drugs like clomiphene and toremiphene. Amiodarone is used in the treatment of heart arrhythmias, is an ion channel blocker, which blocks the ebola virus entry into cells as shown by few

in vitro studies¹⁸. Other promising treatments rely on antisense technology. Both small interfering RNAs (siRNAs) and phosphorodiamidate morpholino oligomers (PMOs) targeting the Zaire Ebola virus (ZEBOV) RNA polymerase L protein could prevent disease in nonhuman primates^{19,20}. TKM-Ebola is a small-interfering RNA compound, currently being tested in a phase I clinical trial in people^{21,22}.

Vaccination

There aren't any vaccinations available as of now but According to BBC News dated 30 August 2014, ZMapp is a Ebola vaccine which shows 100 % success rate, and has been tested on 18 laboratory monkeys, is due to be put through human trials^{23,24}.

AUTHOR'S CONTRIBUTION

All authors have worked equally for this work.

ACKNOWLEDGEMENTS

The authors extend their thanks and appreciation to the Rajiv Gandhi Proudhyogiki Vishwavidyalaya, Bhopal, India to provide necessary facilities for this work.

CONFLICT OF INTEREST

No conflict of interest associated with this work.

REFERENCES

1. WHO. Ebola virus disease Fact sheet No.103. 2014-03-01. Retrieved 2014-04-12.
2. Fauquet CM. Virus taxonomy classification and nomenclature of viruses; 8th report of the International Committee on Taxonomy of Viruses. Oxford: Elsevier/Academic Press. 2005. 648.
3. Epstein L, Wong KK, Kallen AJ, Uyeki TM. Post-Ebola signs and symptoms in U.S. survivors. *N Engl J Med* 2015; 373:2484-6. <https://doi.org/10.1056/NEJMc1506576>
4. Mattia JG, Vandy MJ, Chang JC, et al. Early clinical sequelae of Ebola virus disease in Sierra Leone: a cross-sectional study. *Lancet Infect Dis* 2016; 16:331-8. [https://doi.org/10.1016/S1473-3099\(15\)00489-2](https://doi.org/10.1016/S1473-3099(15)00489-2)
5. Wendo C. Caring for the survivors of Uganda's Ebola epidemic one year on. *Lancet* 2001; 358:1350. [https://doi.org/10.1016/S0140-6736\(01\)06467-4](https://doi.org/10.1016/S0140-6736(01)06467-4)
6. Klenk HD, Feldmann H. Ebola and Marburg Viruses: Molecular and Cellular Biology. Horizon Bioscience. 2004, ISBN 978-1-904933-49-6.
7. Kuhn Jens H, et al. Proposal for a revised taxonomy of the family Filoviridae: Classification, names of taxa and viruses, and virus abbreviations. *Archives Virol* 2010; 155 (12): 2083-103. <https://doi.org/10.1007%2Fs00705-010-0814-x>
8. Nanbo A, Watanabe S, Halfmann P, Kawaoka Y. The spatio-temporal distribution dynamics of Ebola virus proteins and RNA in infected cells. *Nature* 2013. <https://doi.org/10.1038%2Fsrep01206>
9. CDC Telebriefing on Ebola outbreak in West Africa. CDC 2014-07-28. Retrieved 2014-08-03.
10. Harden, Blaine (2001-02-18). Dr. Matthew's Passion. *New York Times Magazine*. Retrieved 2008-02-25.
11. Mehedi M, Falzarano D, Seebach J, Hu XJ, Carpenter MS, Schnittler HJ, et al. A new Ebola virus nonstructural glycoprotein expressed through RNA editing. *J Virol* 2011; 85(11): 5406-14. <https://doi.org/10.1128%2FJVI.02190-10>
12. Olival KJ, Islam A, et al. Ebola virus antibodies in fruit bats, Bangladesh. *Emerg Infect Dis*. 2013; 19(2):270-3.
13. Frieden TR, Damon I, Bell BP, Kenyon T, Nichol S. Ebola 2014-new challenges, new global response and responsibility. *N Engl J Med* 2014; 371(13): 1177-80. <https://doi.org/10.1056/NEJMp1409903>
14. Ebola Hemorrhagic Fever Signs and Symptoms. CDC. 2014-01-28. Retrieved 2014-08-02.
15. Kortepeter MG, Bausch DG, Bray M. Basic clinical and laboratory features of filoviral hemorrhagic fever. *J Infect Dis* 2011; 204 Suppl 3:S810. <https://doi.org/10.1093/infdis/jir299>
16. Ebolavirus and Marburgvirus Infections. The centre for food security and public health, Iowa State University, 2014.
17. Gehring G, et al. The clinically approved drugs amiodarone, dronedarone and verapamil inhibit filovirus cell entry. *J Antimicrob Chemother* 2014; 69 (8): 2123-31. <https://doi.org/10.1093/jac/dku091>
18. Geisbert TW, et al. Post exposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: A proof-of-concept study. *The Lancet* 2010; 375 (9729): 1896-1905. [https://doi.org/10.1016/S0140-6736\(10\)60357-1](https://doi.org/10.1016/S0140-6736(10)60357-1)
19. Warren TK, Warfield KL, et al. Advanced antisense therapies for post exposure protection against lethal filovirus infections. *Nature Medicine* 2010; 16 (9): 991-994. <https://doi.org/10.1038/nm.2202>
20. Pollack, Andrew. Second drug is allowed for treatment of Ebola. *The New York Times*. Retrieved 08-08-2014.
21. Helen Branswell, Nancy Writebol. U.S. missionary didn't get TKM-Ebola drug, Tekmira says. *The Canadian Press*. 2014.
22. Wiwanitkit S, Wiwanitkit V. Ebola vaccine 2014: remained problems to be answered. *Asian Pac J Trop Biomed* 2015; 5(2): 85-86. [https://doi.org/10.1016/S2221-1691\(15\)30149-0](https://doi.org/10.1016/S2221-1691(15)30149-0)
23. Rajak H, Jain DK, Singh A, Sharma AK, Dixit A. Ebola virus disease: past, present and future. *As Pac J Trop Biom* 2015; 5(5): 337-343. [https://doi.org/10.1016/S2221-1691\(15\)30365-8](https://doi.org/10.1016/S2221-1691(15)30365-8)
24. Geisbert TW, Feldmann H. Recombinant vesicular stomatitis virus based vaccines against Ebola and Marburg virus infections. *J Infect Dis* 2011; 204(Suppl 3):S1075-81. <https://doi.org/10.1093%2Finfdis%2Fjir349>